Advanced search×

Clinical evaluation of methoxy-flurane in obstetrical anaesthesia: a report on 500 cases.

M M BOISVERT and F F HUDON

Can Anaesth Soc J (1962) PMID 13870700

Version: za2963e q8za9 q8zb4 q8zca q8zdc q8zed q8zf9 q8zg2

Similar articles you may find interesting…

  1. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarab...
    Marino Clavio, Fabio Cruciani, and Marco Gobbi

    Ann Hematol (2013) PMID 23686116

    We report the final results of a prospective trial testing the combination of fludarabine, Ara-C and idarubicin (FLAI) followed by low-dose gemtuzumab ozogamicin (FLAI-GO) in 85 patients aged 60 years or more with CD33+ acute myeloid leukaemia (AML). Median age was 68 years (60-82); karyotype was un...
  2. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarab...
    Marino Clavio, Fabio Cruciani, and Marco Gobbi

    Ann Hematol (2013) PMID 23686116

    We report the final results of a prospective trial testing the combination of fludarabine, Ara-C and idarubicin (FLAI) followed by low-dose gemtuzumab ozogamicin (FLAI-GO) in 85 patients aged 60 years or more with CD33+ acute myeloid leukaemia (AML). Median age was 68 years (60-82); karyotype was un...
  3. Imidafenacin for the treatment of overactive bladder.
    Umberto Leone Roberti Maggiore, Carolina Scala, and Simone Ferrero

    Expert Opin Pharmacother (2013) PMID 23641864

    Imidafenacin (KRP-197/ONO-8025) is the latest antimuscarinic (AM) developed for the treatment of overactive bladder syndrome (OAB) and, at the moment, it is marketed only in Japan. This compound has been developed to improve the tolerability of AM therapy by binding specifically the M3 receptor subt...